MITI²

The main objective of the MITI2 project is to deliver an immunotherapy product ready to be used in a phase 1 clinical trial to treat IBD patients. The MITI2 project thus aims at provinding a preclinical package including : - the proof of concept that a cellular immunotherapy using the identifies Treg subset represents a clinically suitable treatment for IBD patients - an original gut-explant-based organoid preclinical model, which recapitulates ex vivo the complexity of intestinal physiology, but could also be used for other gut directed drug/cell therapy in the future. This work has been funded by the European Union under the Horizon Europe Programme, as part of the project MITI² (Grant Agreement No. 101080445).